Tags : Max-Planck-Innovation Oncolytic Virotherapies


Themis Biosciences Signs an Exclusive License Agreement with Max-Planck-Innovation for

Shots: Themis to get global rights to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform, collaborately developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry The agreement focus on expanding immunomodulation portfolio for developing multiple immuno-oncology therapeutics The licensed technology is based on the viral genome sequence of […]Read More